Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study

Table 4 Comparison of patients according to 30-d mortality

	< 30-d mortality(n = 16)	≥30-d mortality(n = 17)	P value
Age (yr)	62.9 ± 11.4	68.7 ± 6.6	0.080
Sex
Male	8 (50.0)	9 (52.9)	0.800
Female	8 (50.0)	8 (47.1)
Etiology
HCV	10 (62.5)	13 (76.5)	0.600
Alcohol	3 (18.8)	2 (11.8)
Cryptogenic	3 (18.8)	2 (11.8)
Child-Pugh
B	5 (31.3)	13 (76.5)	0.009
C	11 (68.8)	4 (23.5)
Esophageal varices
Absent	2 (14.3)	2 (14.3)	0.900
F1	8 (57.1)	9 (64.3)
F2	4 (28.6)	3 (21.4)
Diabetes mellitus	6 (37.5)	7 (41.2)	0.800
Hepatocellular carcinoma	3 (18.8)	9 (52.9)	0.040
Portal vein thrombosis	2 (12.5)	5 (29.4)	0.200
Platelets (× 103/mmc)	103.4 ± 87.9	106.1 ± 85.2	0.900
BUN (mg/dL)	134.8 ± 40.5	154.8 ± 76.8	0.300
Creatinine (mg/dL)	3.14 ± 0.8	3.44 ± 1.32	0.400
Creatinine clearance	26 (20-37)	13 (8-24)	0.050
Sodium (mEq/L)	128.5 ± 4.6	132.8 ± 5.5	0.020
Potassium (mEq/L)	4.77 ± 0.87	5.1 ± 0.82	0.200
Urinary sodium (mEq/L)	11 (7-18)	4 (2-13)	0.200
Urinary potassium (mEq/L)	25 (19-29)	15 (10-27)	0.200
Total bilirubin (mg/dL)	10.8 (3.2-21.2)	1.8 (1.5 - 3.6)	0.009
INR	1.6 (1.3-1.7)	1.2 (1.2-1.5)	0.560
MELD score	31 (26-33)	23 (20-26)	0.030
HRS
Type-1	8 (50)	7 (41.2)	0.600
Type-2	8 (50)	10 (58.8)

Data are expressed as absolute n (%), mean ± SD or median (IQR). IQR: Interquartile range; BUN: Blood urea nitrogen; INR: International normalized ratio; MELD: Model for End stage liver disease; HRS: Hepatorenal syndrome.